OncLive - Bringing the Oncology Community Together

Adding ofatumumab (Arzerra) to bendamustine (Treanda) failed to improve progression-free survival in patients with indolent B-cell non-Hodgkin lymphoma who did not respond to rituximab (Rituxan) monotherapy. Read More >>

Expert Recaps Adjuvant Advancements in HER2+ Breast Cancer

Frontline Ibrutinib Plus Obinutuzumab Improves PFS in Phase III CLL Trial

New Strategies Aim at Survival Protein MCL-1

Expert Addresses Advances and Challenges in MDS

FDA Approves New Abiraterone Acetate Formulation for mCRPC

View More Stories >>

View Conference Coverage

2018 ASCO Annual Meeting

2018 ASPHO Conference

2018 State of the Science Summit on Genitourinary Cancers

2018 State of the Science Summit on Gastrointestinal Cancers

2018 State of the Science Summit on Hematologic Malignancies

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

Dr. Ali Explains Misconceptions About Biosimilars

Dr. Urbanic on the Evolution of Radiation in NSCLC

Dr. Ahn on Targeted Therapies in Gastric/Gastroesophageal Cancers

Dr. Godwin on Immunotherapy Efforts in Prostate Cancer

Dr. Monk on the FORWARD I Trial in Ovarian Cancer

Dr. Bekaii-Saab on the Use of Regorafenib in Patients With mCRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Managing Advanced Prostate Cancer in the Future

Hereditary Prostate Cancer Testing in Practice

Improvements in Detecting and Treating Metastatic CRPC

Renal Cell Carcinoma: An Evolving Treatment Landscape

OncLive houses thousands of videos that provide updates and information.
See more Videos

First-Line Therapy in Advanced HCC

$Evaluating Pharmacologic Agents in Relapsed/Refractory CLL$

Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

When to Move to Systemic Therapy in HCC

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

HCC: Role of Radiotherapy and Measuring Response

Future Treatment Strategies in Non-Small Cell Lung Cancer

$Approaching Therapy for Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

The Evolving Landscape of Immunotherapy for NSCLC

A video editorial series that features expert opinions on multiple areas of focus.

View more >>>

Featured

Relapsed/Refractory ALL: Evaluating Novel Agents

$Relapsed/Refractory ALL: Evaluating Novel Agents$
A unique opportunity to view lively discussions featuring peer-to-peer exchanges that provide authoritative insights, opinions, and perspectives on important issues facing today's cancer care professionals.

View more >>>

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approval of Biosimilar, Proposed Change in US Drug Prices, and 2018 ASCO Presscast